Concord Drugs Ltd - 538965 - Clarification On Price Movement
Clarification on Price Movement02-08-2023
02-08-2023
Concord Drugs Ltd - 538965 - Clarification sought from Concord Drugs Ltd
The Exchange has sought clarification from Concord Drugs Ltd on August 1, 2023 with reference to significant movement in price, in order to ensure that investors have latest relevant information about the company and to inform the market so that the interest of the investors is safeguarded.The reply is awaited.01-08-2023
Concord Drugs Ltd - 538965 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Details of Loss of Certificate/Duplicate Certificate24-07-2023
Concord Drugs Ltd - 538965 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate u/r 74(5) for the quarter ended 30.06.202321-07-2023
Concord Drugs Ltd - 538965 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Publication of Financial Results for Fourth quarter and Year ended 31.03.202302-06-2023
Concord Drugs Ltd - 538965 - Audited Financial Results For The Quarter And Year Ended 31.03.2023
Audited Financial Results for the Quarter and Year ended 31.03.202330-05-2023
Concord Drugs Ltd - 538965 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Annual Secretarial Compliance Report for the Financial Year ended 31.03.202330-05-2023
Concord Drugs Ltd - 538965 - Board Meeting Intimation for Audited Financial Results For Quarter And Financial Year Ended 31St March, 2023
Concord Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2023 ,inter alia, to consider and approve Audited Financial Results For Quarter And Financial Year Ended 31St March, 202309-05-2023